Aligos Therapeutics Inc (ALGS)
$7.09
Live
Performance
- $7.09$7.38$7.09
0.0%
Downside
Day's Volatility :3.91%
Upside
3.91%
- $6.76$30.00$7.09
4.65%
Downside
52 Weeks Volatility :77.47%
Upside
76.37%
Returns
| Period | Aligos Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -48.17% | 3.6% | 0.0% |
6 Months | -63.8% | 10.2% | 0.0% |
1 Year | -51.38% | 19.6% | 0.0% |
3 Years | -98.16% | 16.8% | -23.0% |
Highlights
Market Capitalization | 23.0M |
Book Value | $10.91 |
Earnings Per Share (EPS) | -14.5 |
Wall Street Target Price | 103.33 |
Profit Margin | 0.0% |
Operating Margin TTM | -2489.54% |
Return On Assets TTM | -53.97% |
Return On Equity TTM | -110.67% |
Revenue TTM | 8.0M |
Revenue Per Share TTM | 1.65 |
Quarterly Revenue Growth YOY | -84.6% |
Gross Profit TTM | -71.2M |
EBITDA | -91.6M |
Diluted Eps TTM | -14.5 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -6.71 |
EPS Estimate Next Year | -12.58 |
EPS Estimate Current Quarter | -0.16 |
EPS Estimate Next Quarter | 0.02 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 1357.4%
Technicals Summary
Sell
Neutral
Buy
Aligos Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Aligos Therapeutics Inc | -10.49% | -63.8% | -51.38% | -98.16% | -98.05% |
 Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
 Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
 Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
 Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Aligos Therapeutics Inc | NA | NA | NA | -6.71 | -1.11 | -0.54 | NA | 10.91 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Aligos Therapeutics Inc | Buy | $23.0M | -98.05% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Aligos Therapeutics Inc
Increasing Revenue
Revenue is up for the last 2 quarters, 986.0K → 1.06M (in $), with an average increase of 7.1% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -34.86M → 5.06M (in $), with an average increase of 788.9% per quarter
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 144.7%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 143.0%
Institutional Holdings
Armistice Capital, LLC
9.08%EcoR1 Capital, LLC
8.00%Deep Track Capital, LP
7.64%Adage Capital Partners Gp LLC
6.26%Vivo Capital, LLC
4.44%Hillhouse Capital Advisors, Ltd.
3.91%
Company Information
aligos therapeutics, inc., a biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. its lead drug candidate is alg-010133, a synthetic oligonucleotide that is in phase i clinical trial for the treatment of chronic hepatitis b (chb). the company is also developing alg-000184, a capsid assembly modulator to treat chb; alg-020572, a oligonucleotide for the treatment of chb; alg-125097, an sirna drug candidate to treat chb; and alg-055009, a small molecule thr-ã agonist for the treatment of non-alcoholic steatohepatitis. aligos therapeutics, inc. was founded in 2018 and is headquartered in south san francisco, california.
Organization | Aligos Therapeutics Inc |
Employees | 68 |
CEO | Dr. Lawrence M. Blatt MBA, Ph.D. |
Industry | Health Technology |
Discover More
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$7.09
-2.21%
Invesco Bulletshares 2025 Hi
$7.09
-2.21%
Schwab International Dividend Equity Etf
$7.09
-2.21%
Blockchain Coinvestors Acquisition Corp.
$7.09
-2.21%
Allgiant Travel Company
$7.09
-2.21%
Rogers Corp
$7.09
-2.21%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$7.09
-2.21%
Iheartmedia
$7.09
-2.21%
Lightpath Technologies Inc
$7.09
-2.21%